307280.KQ Kyobo 8 Special Purpose Acquisition Company

Healthcare Oil, Gas & Consumable Fuels KOSDAQ
5,500 KRW
Close of Nov 1, 2026
4,669 8,400
Market cap
KRW 37.4B
P/E
4.5x
P/B
0.84x
ROE
20.8%
Dividend yield
1.89%
Fundamental score
3.2/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 307280.KQ undervalued?

Graham number
Price5,500
Graham value13,389
Discount58.9%

307280.KQ trades 58.9% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kyobo 8 Special Purpose Acquisition Company fundamental analysis

16 of 22 checks passed

ROE 2/2

High return on equity (20.8%), above 20%.

ROA 1/1

Return on assets (17.3%) is above the industry median (1.4%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (16.3%) is above the industry median (1.8%).

Revenue Growth 1/2

Revenue grew 9.6% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (3.4%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 162.9x against interest expense, well covered.

PE vs Market 1/1

PE (4.5x) is below the market median (11.3x).

PE vs Industry 1/1

PE (4.5x) is below the industry median (11.4x).

PBV 1/1

Price to book (0.8x) is below the industry median (0.9x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 3.8, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (1.9%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 10.7%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Kyobo 8 Special Purpose Acquisition Company stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kyobo 8 Special Purpose Acquisition Company

Wonbiogen Co., Ltd. manufactures and sells wound dressings in South Korea, rest of Asia, Europe, and internationally. It operates through Wound Dressing and Daily Necessities divisions. The company offers polyurethane foam and hydrocolloid dressings; cosmetics; other dressings; and daily necessities. It also provides medical, organic, and inorganic materials; and laundry detergents. Wonbiogen Co., Ltd. was founded in 2006 and is headquartered in Gumi-si, South Korea.

Full company profile